Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
MAZE Stock Chart & Stats
$44.18
--
Market closed
$44.18
--
Day’s Range― - ―
52-Week Range$6.71 - $49.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.26K
Market Cap
$2.13B
Enterprise Value$1.95B
Total Cash (Recent Filing)$383.94M
Total Debt (Recent Filing)$24.18M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Apr 06, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding48,119,446
10 Day Avg. Volume359,560
30 Day Avg. Volume473,265
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)3.55
Price to Sales (P/S)4.17
P/FCF Ratio9.34
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.00K
Enterprise Value/Ebitda-15.41
Forecast
1Y Price Target
$55.25Price Target Upside25.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$1.71M
Bulls Say, Bears Say
Bulls Say
Early Clinical Efficacy SignalsFavorable early human tolerability and biomarker improvements reported in the HORIZON program provide proof‑of‑concept that MZE829 can reduce proteinuria while supporting once‑daily dosing.
Mechanism Of ActionMZE829's dual mechanism that both blocks existing APOL1 pores and prevents new pore assembly offers a differentiated therapeutic approach versus single‑mechanism inhibitors, which may improve disease control in inflammatory kidney conditions.
Pediatric Labeling And Market ExpansionScientific rationale to bridge adult efficacy data to pediatric APOL1 disease could limit pediatric development to safety and dosing studies, expanding the addressable market and speeding access for children.
Bears Say
Efficacy Uncertainty And Valuation SensitivityBecause the Phase II primary objective focuses on safety and tolerability and patient‑level data remain limited, long‑term efficacy remains uncertain and analyst valuations are vulnerable to later clinical results.
Surrogate Endpoint Validation RequirementsConsensus that longitudinal data are essential to validate surrogate endpoints may require extended follow‑up, increasing development time and regulatory risk.
Trial Population And GeneralizabilityInitial Phase II readout excluding the most severe kidney disease cohort may limit how broadly the results apply and constrain confidence in the drug's benefit across all patients.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $6.71 and its highest was $49.25 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $2.13B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 32 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.708 by $0.048.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.71.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 48,119,446 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.708. Following the earnings report the stock price went down -3.476%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.25 (25.06% Upside)
$55.25 (25.06% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
300.18%
12-Months-Change
Fundamentals
Return on Equity
-36.13%
Trailing 12-Months
Asset Growth
119.27%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$55.25
▲(25.06% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
4.72% Mutual Funds
70.58% Other Institutional Investors
6.38% Public Companies and
Individual Investors